PREDICTIVE ONCOLOGY POAI 深 沪
等待开盘 12-15 09:30:00 美东时间
5.95
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 5.95
- 总市值 2505.78万
- 52周最高 45.90
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.88
- 委 比 0.00%
- 总股本 421.14万
- 历史最高 2550.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 8.25
- 每 手 1
- 风险率 4.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
Axe Compute Inc. has rebranded to Axe Compute Inc. and will trade on Nasdaq under the ticker AGPU. The company aims to expand into high-performance enterprise AI infrastructure, addressing the growing demand for scalable compute capacity. It believes infrastructure, not algorithms, is the bottleneck in AI progress. Axe Compute plans to leverage the Aethir network to secure GPU capacity, offering reliable compute solutions for enterprises. The com...
12-12 13:00
Predictive Oncology Regains Nasdaq Compliance
Predictive Oncology ( ($POAI) ) has provided an update. On December 1, 2025, Pr...
12-03 06:54
Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Predictive Oncology Inc. (NASDAQ: POAI) announced it regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, allowing its shares to continue trading on the Nasdaq Capital Market under "POAI." The company highlighted its progress in strengthening its financial position and preserving investor confidence while expanding its digital asset strategy focused on the Aethir (ATH) token. Predictive Oncology uses AI and ...
12-02 13:00
Predictive Oncology Regains Nasdaq Compliance with Investments
Predictive Oncology ( ($POAI) ) just unveiled an update. Predictive Oncology In...
11-21 06:50
Predictive Oncology Unveils New Digital Asset Strategy
An update from Predictive Oncology ( ($POAI) ) is now available. On November 17...
11-17 21:26
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
Prime Medicine appoints Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer to lead corporate and business development, strategy, and alliance management. With nearly two decades of experience in biotechnology, Hawryluk has a strong track record in securing high-value collaborations and advancing company growth. His expertise will support Prime Medicine's mission to expand the reach of its Prime Editing technology, which aims to correct ge...
11-03 13:01
Predictive Oncology Updates ATM Offering Program
The latest announcement is out from Predictive Oncology ( ($POAI) ). On October...
10-30 05:54
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
Predictive Oncology Inc. has expanded its leadership team and Board of Directors to support its new digital asset treasury strategy centered on the Aethir (ATH) token. Shawn Matthews, CEO of DNA Holdings Venture, Inc. and former CEO of Cantor Fitzgerald, has joined the Board. Thomas McLaughlin, CIO of DNA Holdings, is now the Chief Investment Officer, and Sara Turken, a biopharmaceutical veteran, has been appointed as General Counsel. The company...
10-14 12:00
Predictive Oncology Closes $343.5M Private Placements
Predictive Oncology ( ($POAI) ) has provided an update. On October 8, 2025, Pre...
10-09 00:27
Predictive Oncology Announces $344.4M Private Placements
The latest announcement is out from Predictive Oncology ( ($POAI) ). On Septemb...
09-29 22:18
